B. Riley Comments on biote’s FY2024 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – Investment analysts at B. Riley raised their FY2024 earnings estimates for shares of biote in a report released on Wednesday, November 13th. B. Riley analyst J. Van. Sinderen now anticipates that the company will earn $0.74 per share for the year, up from their prior forecast of $0.50. The consensus estimate for biote’s current full-year earnings is $0.53 per share. B. Riley also issued estimates for biote’s Q4 2024 earnings at $0.06 EPS, FY2025 earnings at $0.47 EPS and FY2026 earnings at $0.70 EPS.

biote Trading Down 2.2 %

BTMD stock opened at $6.57 on Friday. The firm’s 50-day moving average price is $5.53 and its two-hundred day moving average price is $6.28. The stock has a market capitalization of $356.23 million, a price-to-earnings ratio of 25.27 and a beta of 0.94. biote has a 12-month low of $3.65 and a 12-month high of $8.44.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BTMD. Wasatch Advisors LP increased its stake in shares of biote by 8.4% during the third quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock valued at $7,772,000 after buying an additional 107,792 shares during the period. Dimensional Fund Advisors LP boosted its holdings in biote by 1,016.6% in the second quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock valued at $4,931,000 after acquiring an additional 600,956 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in biote by 251.8% in the second quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock valued at $1,442,000 after acquiring an additional 138,200 shares in the last quarter. Sanders Morris Harris LLC raised its holdings in biote by 131.2% in the 3rd quarter. Sanders Morris Harris LLC now owns 180,965 shares of the company’s stock worth $1,010,000 after purchasing an additional 102,706 shares in the last quarter. Finally, Skylands Capital LLC lifted its position in shares of biote by 36.2% in the 2nd quarter. Skylands Capital LLC now owns 160,845 shares of the company’s stock worth $1,202,000 after purchasing an additional 42,729 shares during the period. Institutional investors own 21.68% of the company’s stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.